New review article on mHSPC and mCRPC

Below you will find a link to a valuable new review article on ongoing changes in the opportunities for evaluation and management of men with both hormone-sensitive and castration-resistant, metastatic prostate cancer (mHSPC and mCRPC). … READ MORE …

PREVAIL trial of MDV3100 now fully enrolled

According to information released today by Astellas Pharma and Medivation, the PREVAIL trial of MDV3100 (also now known as enzalutamide) in men with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC) is fully enrolled. .. READ MORE …